Is Orchestra BioMed Stock a Good Investment?
Orchestra BioMed Investment Advice | OBIO |
- Examine Orchestra BioMed's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Orchestra BioMed's leadership team and their track record. Good management can help Orchestra BioMed navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Orchestra BioMed's business and its evolving consumer preferences.
- Compare Orchestra BioMed's performance and market position to its competitors. Analyze how Orchestra BioMed is positioned in terms of product offerings, innovation, and market share.
- Check if Orchestra BioMed pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Orchestra BioMed's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Orchestra BioMed Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Orchestra BioMed Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Orchestra BioMed Stock
Researching Orchestra BioMed's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 22.0% of the company outstanding shares are owned by corporate insiders. The book value of Orchestra BioMed was now reported as 1.22. The company recorded a loss per share of 1.6. Orchestra BioMed Holdings had not issued any dividends in recent years.
To determine if Orchestra BioMed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Orchestra BioMed's research are outlined below:
| Orchestra BioMed had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.76 M. Net Loss for the year was (49.12 M) with profit before overhead, payroll, taxes, and interest of 2.45 M. | |
| Orchestra BioMed generates negative cash flow from operations | |
| About 55.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Orchestra BioMed Projected to Post Earnings on Wednesday |
Orchestra BioMed Quarterly Long Term Debt |
|
Orchestra BioMed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Orchestra BioMed Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Orchestra BioMed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Orchestra BioMed's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Orchestra BioMed's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.4 | -0.45 | -0.05 | 12 | ||
2023-08-10 | 2023-06-30 | -0.41 | -0.35 | 0.06 | 14 | ||
2023-05-12 | 2023-03-31 | -0.28 | -0.4 | -0.12 | 42 | ||
2023-01-25 | 2022-12-31 | -1.71 | -0.08 | 1.63 | 95 |
Orchestra BioMed's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 173.72 M.Market Cap |
|
Orchestra BioMed's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.49) | |
| Return On Capital Employed | (0.55) | (0.58) | |
| Return On Assets | (0.46) | (0.49) | |
| Return On Equity | (0.83) | (0.79) |
Determining Orchestra BioMed's profitability involves analyzing its financial statements and using various financial metrics to determine if Orchestra BioMed is a good buy. For example, gross profit margin measures Orchestra BioMed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Orchestra BioMed's profitability and make more informed investment decisions.
Evaluate Orchestra BioMed's management efficiency
Orchestra BioMed Holdings has return on total asset (ROA) of (0.392) % which means that it has lost $0.392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9166) %, meaning that it created substantial loss on money invested by shareholders. Orchestra BioMed's management efficiency ratios could be used to measure how well Orchestra BioMed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of March 2025, Return On Tangible Assets is likely to drop to -0.49. In addition to that, Return On Capital Employed is likely to drop to -0.58. At this time, Orchestra BioMed's Other Current Assets are very stable compared to the past year. As of the 26th of March 2025, Fixed Asset Turnover is likely to grow to 1.87, while Total Assets are likely to drop about 66.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.84 | 1.94 | |
| Tangible Book Value Per Share | 1.84 | 1.94 | |
| Enterprise Value Over EBITDA | (4.82) | (5.06) | |
| Price Book Value Ratio | 4.01 | 4.21 | |
| Enterprise Value Multiple | (4.82) | (5.06) | |
| Price Fair Value | 4.01 | 4.21 | |
| Enterprise Value | 247 M | 166.5 M |
The operational strategies employed by Orchestra BioMed management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.587 |
Basic technical analysis of Orchestra Stock
As of the 26th of March, Orchestra BioMed holds the Semi Deviation of 5.05, risk adjusted performance of 0.0104, and Coefficient Of Variation of 46684.67. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Orchestra BioMed, as well as the relationship between them.Orchestra BioMed's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orchestra BioMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orchestra BioMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Orchestra BioMed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Orchestra BioMed's Outstanding Corporate Bonds
Orchestra BioMed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Orchestra BioMed Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Orchestra bonds can be classified according to their maturity, which is the date when Orchestra BioMed Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Orchestra BioMed's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Orchestra BioMed's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0104 | |||
| Market Risk Adjusted Performance | 0.0114 | |||
| Mean Deviation | 4.18 | |||
| Semi Deviation | 5.05 | |||
| Downside Deviation | 5.13 | |||
| Coefficient Of Variation | 46684.67 | |||
| Standard Deviation | 6.21 | |||
| Variance | 38.51 | |||
| Information Ratio | 1.0E-4 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 1.0E-4 | |||
| Treynor Ratio | 0.0014 | |||
| Maximum Drawdown | 47.08 | |||
| Value At Risk | (7.76) | |||
| Potential Upside | 6.78 | |||
| Downside Variance | 26.37 | |||
| Semi Variance | 25.53 | |||
| Expected Short fall | (4.19) | |||
| Skewness | 2.51 | |||
| Kurtosis | 13.78 |
| Risk Adjusted Performance | 0.0104 | |||
| Market Risk Adjusted Performance | 0.0114 | |||
| Mean Deviation | 4.18 | |||
| Semi Deviation | 5.05 | |||
| Downside Deviation | 5.13 | |||
| Coefficient Of Variation | 46684.67 | |||
| Standard Deviation | 6.21 | |||
| Variance | 38.51 | |||
| Information Ratio | 1.0E-4 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 1.0E-4 | |||
| Treynor Ratio | 0.0014 | |||
| Maximum Drawdown | 47.08 | |||
| Value At Risk | (7.76) | |||
| Potential Upside | 6.78 | |||
| Downside Variance | 26.37 | |||
| Semi Variance | 25.53 | |||
| Expected Short fall | (4.19) | |||
| Skewness | 2.51 | |||
| Kurtosis | 13.78 |
Consider Orchestra BioMed's intraday indicators
Orchestra BioMed intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Orchestra BioMed stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Orchestra BioMed Corporate Filings
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 19th of February 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify |
Orchestra Stock media impact
Far too much social signal, news, headlines, and media speculation about Orchestra BioMed that are available to investors today. That information is available publicly through Orchestra media outlets and privately through word of mouth or via Orchestra internal channels. However, regardless of the origin, that massive amount of Orchestra data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Orchestra BioMed news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Orchestra BioMed relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Orchestra BioMed's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Orchestra BioMed alpha.
Orchestra BioMed Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Orchestra BioMed can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Orchestra BioMed Corporate Management
| Yuval DSc | GM Therapies | Profile | |
| George Papandreou | Senior Therapies | Profile | |
| Avraham MD | Senior Innovation | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| HansPeter MD | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share | Quarterly Revenue Growth 1.356 | Return On Assets | Return On Equity |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Orchestra BioMed's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.